Scarica l'app Stockscreener
1.87
5.56%
-0.11
Dopo l'orario di chiusura:
1.82
-0.05
-2.67%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Cardiff Oncology Inc Borsa (CRDF) Ultime notizie
What is Zacks Research's Forecast for CRDF FY2027 Earnings? - MarketBeat
CRDF Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cardiff Oncology (NASDAQ:CRDF) Upgraded at Wall Street Zen - MarketBeat
Cardiff Oncology, Inc. (CRDF) - Minichart
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
HC Wainwright Issues Optimistic Outlook for CRDF Earnings - MarketBeat
Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewswire
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC - Defense World
CRDF: Onvansertib shows 72% ORR and robust PFS in RAS-mutated mCRC, advancing to phase III trials - TradingView
Piper Sandler Has Lowered Expectations for Cardiff Oncology (NASDAQ:CRDF) Stock Price - MarketBeat
CRDF: Today's Analyst Ratings and Price Target Adjustment | CRDF Stock News - GuruFocus
Cardiff Oncology advances onvansertib program in colorectal cancer - TipRanks
3 ‘Strong Buy’ Stocks to Buy Today, 2/25/2026, According to Top Analysts - TipRanks
Onvansertib Phase 2 results boost Cardiff Oncology (NASDAQ: CRDF) plans - Stock Titan
Cardiff Oncology Reports Full Year 2025 Results And Provides Business Update - Nasdaq
Cardiff Oncology Q4 2025 Results: Loss of $7.2M Beats Analyst Forecasts | Financial ReportNews and Statistics - IndexBox
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update - Sahm
Cardiff Oncology earnings beat by $0.08, revenue topped estimates - Investing.com Canada
Cardiff Oncology (NASDAQ:CRDF) Announces Quarterly Earnings Results - MarketBeat
Cardiff Oncology: Fourth Quarter Financial Results Overview - Bitget
Cardiff Oncology: Q4 Earnings Snapshot - marketscreener.com
Onvansertib Phase 2 results and 2025 loss at Cardiff Oncology (NASDAQ: CRDF) - Stock Titan
Cardiff Oncology, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - ChartMill
Market Wrap: Does Cardiff Oncology Inc have consistent dividend growthEarnings Recap Report & Growth Focused Stock Reports - baoquankhu1.vn
Cardiff Oncology (CRDF) CAO awarded 200,000 stock options with staged vesting - Stock Titan
Why Cardiff Oncology Inc. (XE7C) stock could be next leaderWeekly Trend Recap & Growth Focused Stock Reports - mfd.ru
Can Cardiff Oncology Inc. stock reach $100 price targetMarket Activity Recap & Safe Entry Trade Signal Reports - mfd.ru
Will Cardiff Oncology Inc. stock outperform tech sector in 2025Weekly Stock Report & Free Community Supported Trade Ideas - mfd.ru
Will Cardiff Oncology Inc. outperform its industry peersQuarterly Portfolio Report & Precise Buy Zone Identification - mfd.ru
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
FY2027 Earnings Estimate for CRDF Issued By Zacks Small Cap - MarketBeat
CRDF: New CEO Presents Phase II Readout - Yahoo Finance
Will Cardiff Oncology Inc. (XE7C) stock justify high valuationM&A Rumor & Growth Focused Entry Reports - mfd.ru
Leadership Turmoil Clouds Clinical Progress at Cardiff Oncology - AD HOC NEWS
Ideas Watch: Is Cardiff Oncology Inc likely to announce a buybackWeekly Gains Summary & Safe Entry Trade Reports - baoquankhu1.vn
Cardiff Oncology (CRDF) Is Down 43.9% After Advancing Onvansertib And Reshuffling Leadership Team - Yahoo Finance
Cardiff Oncology Faces Turbulence Amid Leadership Changes - StocksToTrade
CRDF: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
H.C. Wainwright reiterates Buy rating on Cardiff Oncology stock at $10 - Investing.com Canada
Cardiff Oncology (CRDF) Stock Drop Presents New Investment Oppor - GuruFocus
Why Did Cardiff Oncology Stock Plunge On Tuesday?Cardiff Oncology (NASDAQ:CRDF) - Benzinga
Investors Buy High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF) - Defense World
Cardiff Oncology appoints interim CEO amid leadership transition By Investing.com - Investing.com India
Cardiff To Pursue Narrower CRC Market For Onvansertib As Top Execs Step Down - Citeline News & Insights
Cardiff Oncology Overhauls Leadership to Advance Onvansertib - TipRanks
Favorite son in PLK1? Cardiff dips as phase II CRC bid advances - BioWorld MedTech
CEO transition at Cardiff Oncology (NASDAQ: CRDF) paired with positive Phase 2 trial - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Cardiff Oncology (CRDF) Shares Plunge After Executive Departures and Trial Update - GuruFocus
Cardiff Oncology Shares Plunge 35% Following CEO and CFO Resignations - Intellectia AI
Cardiff Oncology Sees Unusually Large Options Volume (NASDAQ:CRDF) - MarketBeat
Cardiff Oncology Taps Interim CEO, Picks 30mg Onvansertib Regimen for 2026 Registrational mCRC Study - MarketBeat
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development - The Globe and Mail
Cardiff Oncology down after leadership shakeup (CRDF:NASDAQ) - Seeking Alpha
Cardiff Oncology stock tumbles after Phase 2 trial data update By Investing.com - Investing.com Canada
Cardiff Oncology plunges after top executives step down - TradingView
Cardiff Oncology (CRDF) Reports Promising Phase 2 Trial Results - GuruFocus
Cardiff Oncology reports positive phase 2 data for cancer drug - Investing.com
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):